Skip to Content
scroll

Clinuvel Pharmaceuticals (CUV)

ASX.CUV $11.35

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CUV $11.35

20 MINUTE DELAYED

TODAY

-0.44 %

1 YEAR RETURN

0.00%

VOLUME

88,568

DIV YIELD

0.44%

PE RATIO

15.94

52 WEEK RANGE

11.04

17.71

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

11.35

Change

-0.05 (-0.44)

Bid / Ask

11.24 - 11.45

Volume

88,568

Turnover

992,527

Open

11.22

Day Range

11.06 - 11.40

VWAP

11.21

Prev Close

11.40

Last Trade

17/02 4:10pm (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

41,444,643

NTA/Share

0.00

Last Dividend

0.05

Dividend Ex Date

05 SEP 2024

Dividend Pay Date

20 SEP 2024

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.44

Market Cap

0

Price to Earnings Ratio (P/E)

15.94

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. Its principal activity consists of commercializing and distribution in Europe and the United States, Israel, and Australia of its drug candidate SCENESSE for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top